The WHO Constitution states its main objective as "the attainment by all peoples of the highest possible level of health". Headquartered in Geneva, Switzerland, it has six regional offices and 150 field offices worldwide.The WHO was established on 7 April 1948. The first meeting of the World Health Assembly (WHA), the agency's governing body, took place on 24 July of that year. The WHO incorporated the assets, personnel, and duties of the League of Nations' Health Organization and the Office International d'Hygiène Publique, including the International Classification of Diseases (ICD). Its work began in earnest in 1951 after a significant infusion of financial and technical resources.The WHO's mandate seeks and includes: working worldwide to promote health, keeping the world safe, and serve the vulnerable. It advocates that a billion more people should have: universal health care coverage, engagement with the monitoring of public health risks, coordinating responses to health emergencies, and promoting health and well-being. It provides technical assistance to countries, sets international health standards, and collects data on global health issues. A publication, the World Health Report, provides assessments of worldwide health topics. The WHO also serves as a forum for discussions of health issues.The WHO has played a leading role in several public health achievements, most notably the eradication of smallpox, the near-eradication of polio, and the development of an Ebola vaccine. Its current priorities include communicable diseases, particularly HIV/AIDS, Ebola, COVID-19, malaria and tuberculosis; non-communicable diseases such as heart disease and cancer; healthy diet, nutrition, and food security; occupational health; and substance abuse. Its World Health Assembly, the agency's decision-making body, elects and advises an executive board made up of 34 health specialists. It selects the director-general, sets goals and priorities, and approves the budget and activities. The current director-general is Tedros Adhanom Ghebreyesus of Ethiopia.The WHO relies on contributions from member states (both assessed and voluntary) and private donors for funding. Its total approved budget for 2020–2021 is over $7.2 billion, of which the majority comes from voluntary contributions from member states. Contributions are assessed by a formula that includes GDP per capita. Among the largest contributors were Germany (which contributed 12.18% of the budget), the Bill & Melinda Gates Foundation (11.65%), and the United States (7.85%).Since the late 20th century, the rise of new actors engaged in global health such as the World Bank, the Bill & Melinda Gates Foundation, the US President's Emergency Plan for AIDS Relief (PEPFAR) and dozens of public-private partnerships for global health have weakened the WHO's role as a coordinator and policy leader in the field.
Limited evidence exists on the combined effects of lifestyle factors on breast cancer (BC) risk, particularly in developing countries. This study aimed to investigate the association between adherence to the World Cancer Research Fund and the American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations and BC risk among Moroccan women. We conducted a large case-control study including 1,400 cases and 1,400 matched controls (by age and place of residence) between 2019 and 2023. A structured general questionnaire and a validated Food Frequency Questionnaire were used for data collection. Adherence to cancer prevention recommendations was assessed using a score ranging from 0 to 7, comprising seven components covering dietary patterns, physical activity, healthy weight, and breastfeeding. Multivariable logistic regression models were used to estimate OR and 95 % CI, accounting for potential confounding variables. For each one-point increase in the WCRF/AICR adherence score, the odds of BC decreased by 67 % overall (OR = 0·33; 95 % CI: 0·29-0·37). This inverse association was consistent among both premenopausal women (OR = 0·29; 95 % CI: 0·24-0·35) and postmenopausal women (OR = 0·35; 95 % CI: 0·30-0·41). Analysis of individual recommendations indicated that physical activity, maintaining a healthy weight, breastfeeding, consuming a plant-rich diet, and limiting the intake of fast and other processed foods were the main drivers of the observed inverse association with BC. In conclusion, greater adherence to the WCRF/AICR recommendations is associated with a reduced risk of breast cancer in Morocco. Prevention strategies should incorporate comprehensive interventions targeting multiple lifestyle factors.
BACKGROUND:The World Health Organization (WHO) currently endorses several commercial interferon-gamma release assays (IGRAs); policy updates are needed given the development of new tests. We conducted an updated systematic review and meta-analysis to compare sensitivity, specificity, and agreement of newly commercialized IGRAs with WHO-endorsed IGRAs. METHODS:Databases (Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and International Clinical Trials Registry Platform) were searched for studies published from 1 February 2021 to 30 September 2024, then again up to 16 December 2025. We included cross-sectional, cohort, and case-control studies and assessed risk of bias using QUADAS-2. The primary outcomes were pooled differences in sensitivity, specificity, and agreement between the new IGRAs and WHO-endorsed IGRAs. RESULTS:From 3039 records screened, 39 reports (36 published) describing 8 new IGRAs met eligibility: STANDARD E TB-Feron, LIAISON XL Analyzer (chemiluminescence immunoassay [CLIA]), Ichroma IGRA-TB, STANDARD F TB-Feron, VIDAS TB-IGRA, ASACIR.TB, Wantai CLIA, and AdvanSureI3 TB-IGRA. STANDARD E TB-Feron had nonsignificantly lower sensitivity (-2.8% [95% confidence interval {CI}, -11.8% to 6.2%]) and specificity (-3.6% [95% CI, -10.0% to 2.7%]), with kappa of 0.802 (95% CI, .729-.874]), compared to QFT-Plus. For LIAISON XL Analyzer, the specificity was 0.1% higher (95% CI, -6.2% to 6.4%) than QFT-Plus/QFT-GIT, with a pooled kappa of 0.846 (95% CI, .814-.878). CONCLUSIONS:Two of the 8 new tests reviewed showed promising accuracy and high agreement with WHO-endorsed IGRAs. The overall certainty of evidence remains low due to risk of bias and imprecision. High-quality, independent studies in diverse populations and settings are needed to inform future WHO recommendations for tuberculosis infection tests. Clinical Trials Registration. PROSPERO (CRD42024544404).
Regularly updating repositories of air pollution impacts on health is essential for evidence-based policies, interventions, and progress monitoring. However, this is often time-consuming and labour-intensive. Automation can ensure up-to-date evidence; reduce retrieval, screening time, and costs; and make information accessible to non-academic stakeholders. This study investigated whether a machine learning approach can perform any stages of a traditional scoping review on the health impacts, policies, and interventions related to air pollution due to domestic waste burning. A traditional approach was conducted in parallel with machine learning methods enabling a comparison of the efficiency and quality of the partially automated approach against the manual review. Findings from the two approaches were compared and the final set of included articles were considered for (1) reported impacts of waste burning on health outcomes and (2) recommendations on solutions and interventions to prevent/reduce adverse effects on health from waste burning. We found a range of health impacts associated with waste burning, including low birth weight, hypertensive disorders of pregnancy, adverse respiratory outcomes like asthma and wheeze, cancer risk, and mortality. Few studies proposed solutions or evaluated the effectiveness of interventions. The ML approach showed a tendency towards false positives, which are preferable to false negatives (where relevant papers were excluded). Results showed that the model can conduct initial searches and decisions for the review. However, the articles included in the model should be screened manually for final acceptance. Therefore, we propose a hybrid approach be used until the automated model can be further refined.
Abstract Background Timely, accurate tuberculosis (TB) diagnostics and strong laboratory networks are critical for providing high-quality TB care. In the Western Pacific Region, available resources, TB burdens, and access to TB testing vary dramatically between countries. To understand the current regional situation, we described TB diagnostic test availability and laboratory services in seven countries with high TB burdens in the Western Pacific Region: Main text In 2024, World Health Organization’s (WHO) Western Pacific Regional Office conducted an assessment of TB diagnostic test availability and laboratory services in seven countries with high TB burdens: Cambodia, China, Lao People’s Democratic Republic, Mongolia, Philippines, Papua New Guinea, and Viet Nam. Standardised surveys were sent to members of country national tuberculosis programmes, and follow-up interviews were conducted. An in-person workshop was attended where preliminary findings were presented and updated, if necessary. The exercise revealed a high uptake of WHO-endorsed rapid molecular tests for TB detection, although the use of smear microscopy persists in most countries’ remote areas. Regarding drug susceptibility testing, both molecular and phenotypic methods are employed. Testing for first-line TB drug resistance is generally available, but currently, testing capacity for new and re-purposed drugs remains limited. Most countries provide TB testing at district-level facilities in conjunction with well-established specimen transport networks, with laboratories utilising a mix of paper and electronic databases. Comprehensive TB and drug-resistance testing at peripheral settings remains a rarity. Conclusions The Western Pacific Region has invested significantly in TB testing and laboratory services. To ensure everyone in the region has access to TB diagnostics, these efforts must be maintained.
Abstract Background Mental health (MH) disorders remain a major global public health concern, disproportionately affecting adolescents and young people living with HIV (AYPLHIV). Limited access to MH services, stigma, and a shortage of trained professionals hinder effective care, particularly in low-resource settings. Mobile health (mHealth) applications have emerged as accessible and scalable tools for improving MH support and reducing disparities in service delivery. This systematic review assessed the effectiveness of mHealth applications in improving access to MH services and outcomes among AYPLHIV and comparable populations globally. Methods A systematic search was conducted across PubMed, PsycINFO, Web of Science, and the Cochrane Library for studies published between January 2020 and March 2025. Eligible studies evaluated mobile or app-based interventions designed to enhance MH access, engagement, or outcomes. Systematic reviews, meta-analyses, SMS-only interventions, and non-empirical studies were excluded. Two independent reviewers (CM and PS) screened articles, extracted data, and assessed study quality using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Data were synthesized narratively following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 framework. Results Of 265 records identified, 16 empirical studies met the inclusion criteria. The studies covered Africa (Ethiopia, Kenya), Asia (Indonesia, Vietnam, Iran, Malaysia), Europe (Spain, Poland, United Kingdom), North America (USA), and Oceania (Australia), and employed randomized controlled trials, mixed-methods, pre–post, and cross-sectional designs. Across studies, mobile interventions consistently improved user engagement, accessibility, and MH outcomes, including significant reductions in depression, anxiety, and stress symptoms (p < 0.05). Peer-based models delivered via WhatsApp demonstrated high feasibility and acceptability among AYPLHIV, while cognitive behavioral therapy (CBT) and mindfulness-based apps such as IntelliCare and Headspace produced outcomes comparable to traditional care in several settings. Key facilitators included personalization, app usability, and human or AI-enabled feedback (e.g., chatbot support), while barriers included privacy concerns, connectivity constraints, and low digital literacy. Conclusions mHealth applications substantially improve access to and delivery of MH services for AYPLHIV and related groups. Integration of these tools into existing health systems, combined with culturally tailored design, ethical AI use, and sustainability strategies, can strengthen MH care globally. Future research should address long-term impact, cost-effectiveness, and equity in implementation.
